Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmac... (

Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA

Date:5/7/2009

- CORNERSTONE GAINS EXCLUSIVE 10-YEAR LICENSE FOR U.S. COMMERCIAL RIGHTS TO MARKETED RESPIRATORY DRUG, CUROSURF(R), AND RECEIVES CASH PROCEEDS OF $15.5 MILLION

- CORNERSTONE RECEIVES FIRST RIGHT OF OFFER ON ALL CHIESI DRUGS INTENDED TO BE COMMERCIALIZED IN THE U.S.

CARY, N.C., May 7 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq CM: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription medications primarily for respiratory indications, today announced a strategic transaction with Chiesi Farmaceutici SpA, a leading European pharmaceutical company headquartered in Parma, Italy, valued at $70 million, based on the 10-day average closing share price of Cornerstone. Under the terms of the agreement, Cornerstone will issue 11.9 million shares of common stock and receive an exclusive 10-year license with renewable rights for the U.S. commercial rights to Chiesi's Curosurf(R) product, the world leading treatment approved by the U.S. Food and Drug Administration (FDA) for Respiratory Distress Syndrome (RDS) in premature infants, and $15.5 million in cash. Cornerstone will also receive first right of offer on all new products and technology Chiesi intends to market in the U.S.

This transaction enables Cornerstone to:

Further diversify its revenue base by adding an FDA approved marketed product, Curosurf, with a leading market position and a proprietary manufacturing process;
Broaden its respiratory therapeutic reach and customer base;
Strengthen the Company's balance sheet; enabling Cornerstone to accelerate the development of its existing product pipeline, evaluate additional opportunities to enhance its product portfolio and support further growth in its sales force to expand reach; and
Establish a long-term relationship with a leading European pharmaceutica
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
2. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
3. Cornerstone Therapeutics Announces New Board of Directors
4. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
5. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
6. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
7. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
8. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel
9. Royer Animal Health Enters Into Exclusive Agreement With MWI Veterinary Supply for U.S. Distribution of Next-Generation Therapeutics to Treat Cancer and Infections
10. Prime Therapeutics Announces Departure of President and Chief Executive Officer Timothy Dickman
11. InteRNA Technologies and Radboud University Nijmegen Medical Centre to Develop microRNA-based Therapeutics for Prostate Cancer

Post Your Comments:

Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmac...( - CORNERSTONE GAINS EXCLUSIVE 10-YEAR...),Health